Public procurement notice: Contract Notice
Published: 2019-08-05
Buyer: The Common Services Agency (more commonly known as NHS National Services Scotland) (‘NSS’)
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 1684296 GBP
Submission deadline: 2019-09-04
Award criteria: The most economic tender

Technical requirements: All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any integrated joint boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
This framework agreement is for the supply of Teriparatide to NHS Scotland. This will require supply of the goods direct to hospitals and nominated home delivery supplier(s) as directed by the authority.
The framework agreement includes the provision of goods only and goods with manufacturer funded homecare. Each product line will be treated as an individual lot and will be awarded on a line by line basis. It is envisaged that each lot will be awarded as an unranked multi supplier framework to a maximum of three (3) framework participants.
The authority is entitled at its sole discretion to extend the framework agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in Regulation 58 of the Public Contracts (Scotland) Regulations 2015.
(a) potential framework participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Goods for the commencement of the framework agreement;
(b) potential framework participants and any subcontractor(s) must possess valid certification of BS EN ISO 9001 or equivalent;
(c) all tendered goods must comply with the MHRA best practice guidance on labelling and packaging and the National patient safety agency (‘NPSA’) guidelines on packaging and Labelling on pack design;
(d) potential framework participants must be able to demonstrate that all ancillaries tendered under this Framework Agreement are CE marked.
(a) confirmation that a valid and current UK Marketing Authorisation or EMA marketing Authorisation that has been approved by the MHRA for all tendered goods will be in place for the start date of the framework agreement should be included in the qualification envelope of the ITT under the technical and professional ability: quality control;
(b) confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the qualification envelope of the ITT under technical and professional ability: quality assurance schemes;
(c) confirmation that samples for tendered goods will be supplied upon request to ensure compliance with the MHRA best practice guidance on labelling and packaging and the National patient safety agency (‘NPSA’) guidelines on packaging and labelling on pack design. Confirmation of sample provision should be provided in the qualification envelope of the ITT under technical and professional ability: products;
(d) confirmation that ancillaries submitted and classed as medical devices will carry the appropriate CE declaration of conformity prior to the start date of the framework agreement should be included in the qualification envelope of the ITT under technical and professional ability: quality control.
The estimated values referred to in Sections II.I.5) and II.2.6) cover the initial twelve (12) month duration and the maximum twenty four (24) months extension period.
The authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful. The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notice(s) and the date on which the authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

Eligibility requirements: Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in Regulation 58 of the Public Contracts (Scotland) Regulations 2015.

Award value: 1684296